MétaCan
Menu
← Back to cohort
Record W2897580988 · doi:10.1016/j.jalz.2018.06.074

P1‐072: PRE‐CLINICAL CHARACTERIZATION OF HUMANIZED, BLOOD‐BRAIN BARRIER (BBB)‐PENETRATING, AMYLOID‐β (Aβ) OLIGOMER‐TARGETING FUSION PROTEIN

2018· article· en· W2897580988 on OpenAlexaff
Kerry Rennie, Trevor Atkinson, Leslie Brown, Michel Ménard, Eric Brunette, Alex Pelletier, Susan X. Jiang, Ewa Baumann, Christie E. Delaney, Eric Grazzini, Arsalan S. Haqqani, Étienne Lessard, Pedro Rosa‐Neto, John W. Gillard, Nathan Yoganathan, Krishnaraj Tiwari, Donald Paquette, Mehul D. Patel, Yves Durocher, Danica Stanimirovic, Balu Chakravarthy

Bibliographic record

VenueAlzheimer s & Dementia · 2018
Typearticle
Languageen
FieldComputer Science
TopicComputational Drug Discovery Methods
Canadian institutionsKingston Health Sciences CentreMcGill UniversityNational Research Council Canada
Fundersnot available
KeywordsBlood–brain barrierWestern blotChemistryTransgeneFusion proteinIn vivoGenetically modified mouseMolecular biologyBlotPharmacologyRecombinant DNABiochemistryBiologyCentral nervous systemEndocrinology

Abstract

fetched live from OpenAlex

A 40-amino acid peptide (ABP) that selectively binds Aß1-42 oligomers and Aß deposits in brains of Alzheimer's disease (AD) patients and AD transgenic mice, was shown to effectively lower CSF and brain Aß levels after systemic dosing in transgenic mice and rats when fused to the blood-brain barrier (BBB)-crossing single-domain antibody FC5. The fusion protein was subsequently humanized and further engineered for development as human therapeutic (KAL-ABP-BBB). Present studies show pre-clinical characterization of the KAL-ABP-BBB in transgenic mice and aged dogs. Recombinant non-humanized [KAL-ABP-BBB(M)] and humanized [KAL-ABP-BBB(H)] proteins were produced in CHO cells. BBB-permeability was assessed using in vitro BBB (formed by rat or human brain endothelial cells) and in vivo (rat and mouse) models. Aß binding was determined by ELISA, Western blot overlay and immunohistochemical methods. Serum, CSF and brain levels of systemically dosed KAL-ABP-BBB constructs and Aß were assessed by nanoLC-MRM, ELISA and Western blot. Both KAL-ABP-BBB bi-functional fusion proteins expressed in CHO cells retained Aß-oligomer binding activity and BBB-permeability in vitro. After systemic dosing, both KAL-ABP-BBB versions demonstrated identical long serum pharmacokinetics in rats and were detected in CSF, cortex and hippocampus of naïve and transgenic mice. In transgenic mice, treatment with either variant of KAL-ABP-BBB resulted in a significant (∼50%) reduction of Aß levels in the CSF suggesting in vivo target engagement. The ability of each variant to engage naturally occurring Aß was further shown after brain microinjection in live animals. Translational studies in aged dogs, which exhibit elevated levels of Aß (identical to human Aß), demonstrated similar serum PK to that observed in rats, >20-fold increased CSF exposure compared to control fusion protein, as well as a reduction in CSF levels of Aß, indicating target engagement. The study demonstrates translation of results (serum PK, enhanced CNS exposure, and lowering of Aß) obtained with KAL-ABP-BBB (M) in rodent species to aged dogs. Chakravarthy et al., J. Neurochem 126, 415, 2013. Biochem. Biophys. Res. Commun. 445, 656, 2014.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.031
GPT teacher head0.322
Teacher spread0.291 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & Dementia→Same topicComputational Drug Discovery Methods→French-language works237,207→